MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC ...
YL201, a B7H3-targeting ADC, showed encouraging antitumor activity in SCLC (ORR 68.1%, mPFS 6.2 months), NPC, and wild-type NSCLC in Phase I studies. Presented at ESMO 2024, YL201 is developed on MediLink’s TMALIN® platform.
Related Clinical Trials
Reference News
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC ...
YL201, a B7H3-targeting ADC, showed encouraging antitumor activity in SCLC (ORR 68.1%, mPFS 6.2 months), NPC, and wild-type NSCLC in Phase I studies. Presented at ESMO 2024, YL201 is developed on MediLink’s TMALIN® platform.